Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma

被引:77
作者
Yamshchikov, GV
Mullins, DW
Chang, CC
Ogino, T
Thompson, L
Presley, J
Galavotti, H
Aquila, W
Deacon, D
Ross, W
Patterson, JW
Engelhard, VH
Ferrone, S
Slingluff, CL
机构
[1] Univ Virginia, Hlth Sci Ctr, Dept Surg, Charlottesville, VA 22908 USA
[2] Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA
[3] Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA
[4] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA
[5] Univ Virginia, Ctr Canc, FACS, Charlottesville, VA 22908 USA
[6] Roswell Pk Canc Inst, Dept Immunol, Rochester, NY 14623 USA
关键词
D O I
10.4049/jimmunol.174.11.6863
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immune-mediated control of tumors may occur, in part, through lysis of malignant cells by CD8(+) T cells that recognize specific Ag-HLA class I complexes. However, tumor cell populations may escape T cell responses by immune editing, by preventing formation of those Ag-HLA complexes. It remains unclear whether the human immune system can respond to immune editing and recognize newly arising escape variants. We report an example of shifting immune responses to escape variants in a patient with sequential metastases of melanoma and long-term survival after surgery alone. Tumor cells in the first metastasis escaped immune recognition via selective loss of an HLA haplotype (HLA-A11, -B44, and -Cw17), but maintained expression of HLA-A2. In the second metastasis, immune escape from an immunodominant MART-1-specific T cell response was mediated by HLA class I down-regulation, resulting in a failure to present this epitope, but persistent presentation of a tyrosinase-derived epitope. Consequent to this modification in tumor Ag presentation, the dominant CTL response shifted principally toward a tyrosinase-targeted response, even though tyrosinase-specific CTL had been undetectable during the initial metastatic event. Thus, in response to immune editing of tumor cells, a patient's spontaneous T cell response adapted, gaining the ability to recognize and to lyse '' edited '' tumor targets. The observation of both immune editing and immune adaptation in a patient with long-term survival after surgery alone demonstrates an example of immune system reactivity to counteract the escape mechanism(s) developed by tumor cells, which may contribute to the clinical outcome of malignant disease.
引用
收藏
页码:6863 / 6871
页数:9
相关论文
共 40 条
[1]  
BAKKER ABH, 1995, INT J CANCER, V62, P97
[2]   PRODUCTION OF MONOCLONAL ANTIBODIES TO GROUP-A ERYTHROCYTES, HLA AND OTHER HUMAN CELL-SURFACE ANTIGENS - NEW TOOLS FOR GENETIC-ANALYSIS [J].
BARNSTABLE, CJ ;
BODMER, WF ;
BROWN, G ;
GALFRE, G ;
MILSTEIN, C ;
WILLIAMS, AF ;
ZIEGLER, A .
CELL, 1978, 14 (01) :9-20
[3]  
BLUMTIROUVANZIAM U, 1995, J IMMUNOL, V154, P3922
[4]   A NEW GENE CODING FOR A DIFFERENTIATION ANTIGEN RECOGNIZED BY AUTOLOGOUS CYTOLYTIC T-LYMPHOCYTES ON HLA-A2 MELANOMAS [J].
COULIE, PG ;
BRICHARD, V ;
VANPEL, A ;
WOLFEL, T ;
SCHNEIDER, J ;
TRAVERSARI, C ;
MATTEI, S ;
DEPLAEN, E ;
LURQUIN, C ;
SZIKORA, JP ;
RENAULD, JC ;
BOON, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :35-42
[5]   IDENTIFICATION OF A PEPTIDE RECOGNIZED BY 5 MELANOMA-SPECIFIC HUMAN CYTOTOXIC T-CELL LINES [J].
COX, AL ;
SKIPPER, J ;
CHEN, Y ;
HENDERSON, RA ;
DARROW, TL ;
SHABANOWITZ, J ;
ENGELHARD, VH ;
HUNT, DF ;
SLINGLUFF, CL .
SCIENCE, 1994, 264 (5159) :716-719
[6]   Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy [J].
Engelhard, VH ;
Bullock, TNJ ;
Colella, TA ;
Sheasley, SL ;
Mullins, DW .
IMMUNOLOGICAL REVIEWS, 2002, 188 :136-146
[7]   LOSS OF HLA CLASS-I ANTIGENS BY MELANOMA-CELLS - MOLECULAR MECHANISMS, FUNCTIONAL-SIGNIFICANCE AND CLINICAL RELEVANCE [J].
FERRONE, S ;
MARINCOLA, FM .
IMMUNOLOGY TODAY, 1995, 16 (10) :487-494
[8]   HLA-A2.1-ASSOCIATED PEPTIDES FROM A MUTANT-CELL LINE - A 2ND PATHWAY OF ANTIGEN PRESENTATION [J].
HENDERSON, RA ;
MICHEL, H ;
SAKAGUCHI, K ;
SHABANOWITZ, J ;
APPELLA, E ;
HUNT, DF ;
ENGELHARD, VH .
SCIENCE, 1992, 255 (5049) :1264-1266
[9]   Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor [J].
Ikeda, H ;
Lethe, B ;
Lehmann, F ;
VanBaren, N ;
Baurain, JF ;
DeSmet, C ;
Chambost, H ;
Vitale, M ;
Moretta, A ;
Boon, T ;
Coulie, PG .
IMMUNITY, 1997, 6 (02) :199-208
[10]  
Jäger E, 2000, INT J CANCER, V86, P538